Review of Ceftazidime-Avibactam for the Treatment of Infections Caused by <i>Pseudomonas aeruginosa</i>
<i>Pseudomonas aeruginosa</i> is an opportunistic Gram-negative pathogen that causes a range of serious infections that are often challenging to treat, as this pathogen can express multiple resistance mechanisms, including multidrug-resistant (MDR) and extensively drug-resistant (XDR) ph...
Main Authors: | George L. Daikos, Clóvis Arns da Cunha, Gian Maria Rossolini, Gregory G. Stone, Nathalie Baillon-Plot, Margaret Tawadrous, Paurus Irani |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-09-01
|
Series: | Antibiotics |
Subjects: | |
Online Access: | https://www.mdpi.com/2079-6382/10/9/1126 |
Similar Items
-
In vitro activity of ceftazidime/avibactam against ceftazidime-resistant Enterobacterales and Pseudomonas aeruginosa from hospitalised patients in Germany
by: Michael Kresken, et al.
Published: (2021-06-01) -
Ceftazidime-Avibactam as Osteomyelitis Therapy: A Miniseries and Review of the Literature
by: Alessandro Mancuso, et al.
Published: (2023-08-01) -
Ceftazidime/avibactam: a novel cephalosporin/nonbeta-lactam beta-lactamase inhibitor for the treatment of complicated urinary tract infections and complicated intra-abdominal infections
by: Hidalgo JA, et al.
Published: (2016-07-01) -
Ceftazidime/Avibactam for the Treatment of Carbapenem-Resistant Pseudomonas aeruginosa Infection in Lung Transplant Recipients
by: Chen J, et al.
Published: (2023-04-01) -
Cost-Effectiveness of Short Course of Ceftazidime/Avibactam for <i>K. pneumoniae</i>-KPC Bloodstream Infections in Italy
by: Ilaria De Benedetto, et al.
Published: (2023-04-01)